APR 06, 2020 6:52 AM PDT

Clearing the Path for Dendritic Cells to Eliminate Tumors

WRITTEN BY: Tara Fernandez

Dendritic cells are the sentinels of the immune system and use their “tree-like” projections to present antigens from pathogens to initiate the adaptive immune response. During cancer, dendritic cells are suppressed by chemical factors around the periphery of tumors, allowing these masses to grow and spread. On top of that, a subset of dendritic cells that are known to suppress the immune system is often recruited to the tumor site, limiting the ability of other immune cells to infiltrate and stall tumor growth.

Can we interrupt the tumor’s ability to evade the immune system? This is a question driving research at Mount Sinai, where scientists recently uncovered a molecular pathway that cancers use to block the infiltration and activities of dendritic cells. The team, led by Miriam Merad, Director of Mount Sinai’s Precision Immunology Institute also identified ways to leverage this pathway to boost cancer immunotherapy. The study was published in Nature.

The team used single-cell sequencing and state-of-the-art microscopy techniques to study human lung tumors as well as a mouse lung cancer model. They were particularly interested in the complex dynamics of dendritic cells and cancer cells at the interface of tumors and the healthy surrounding tissues. These interactions involved the interplay between multiple immune cells, particularly affecting the ability of T cells to destroy cancer cells. Cytotoxic lymphocytes, mainly cytotoxic T cells and natural killer cells have the ability to eradicate tumors. But first, they have to “see” them, with the help of dendritic cells. Merad and team identified chemical signals and molecular interactions involved in the breakdown of communication between dendritic cells and T cells at the tumor site.

These findings shed light on a contributing factor to why so many patients fail to respond to immunotherapies, a form of treatment that boosts the body's natural defenses against cancer. Currently, only about 20 percent of patients show signs of improvement following a form of immunotherapy called checkpoint blockades. By combining existing therapies with a second pharmaceutical intervention that overrides the suppression of dendritic cell activity at the tumor site, researchers are optimistic that this will drastically improve patient outcomes. A clinical trial to test this approach is being designed, in collaboration with biotech company, Regeneron.

"This study highlights the power of single-cell technologies to identify new therapeutic targets in cancer," says Merad.

 


 

Sources: Science Daily, Nature.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
NOV 04, 2021
Cancer
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
NOV 04, 2021
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
Despite the incremental success immune checkpoint inhibitors (ICI) have attributed to the cancer treatment landscape rec ...
NOV 18, 2021
Immunology
Ultrasound Helps Shuttle Cancer-Killing Antibodies to the Brain
NOV 18, 2021
Ultrasound Helps Shuttle Cancer-Killing Antibodies to the Brain
Antibody therapies harness the immune system's power to fight a broad spectrum of diseases, from cancer to infectiou ...
NOV 25, 2021
Immunology
What's a T Cell COVID Vaccine and Could It Be Better Than What We Have?
NOV 25, 2021
What's a T Cell COVID Vaccine and Could It Be Better Than What We Have?
All vaccines train the immune system to recognize and wage war against pathogens such as viruses and bacteria. However, ...
DEC 02, 2021
Microbiology
Antibodies Seem to Keep Gut Fungi in Check, Except in Crohn's Patients
DEC 02, 2021
Antibodies Seem to Keep Gut Fungi in Check, Except in Crohn's Patients
The bacteria that live in the gut microbiome have gotten a lot of attention, and for good reason; gut bacteria have been ...
JAN 06, 2022
Health & Medicine
New Hope for Hair Regrowth in Alopecia Areata
JAN 06, 2022
New Hope for Hair Regrowth in Alopecia Areata
Two recently completed phase 3 clinical trials showed the drug baricitinib leads to hair growth for alopecia areata pati ...
JAN 17, 2022
Cancer
High Fiber Diet Provides a Helpful Boost to Melanoma Treatment
JAN 17, 2022
High Fiber Diet Provides a Helpful Boost to Melanoma Treatment
Immune checkpoint inhibitors (ICIs) have become a promising new treatment for advanced cancers, including melanoma. Immu ...
Loading Comments...